Retinopathy News and Research

RSS

GI Dynamics' EndoBarrier non-surgical type 2 diabetes therapy receives European CE mark approval

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier™, a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French "Conformite Europeenne") certifies that a product has met EU requirements for marketing in Europe. Clinical trials involving more than 270 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner.

22 Dec 2009

Reference platform for diabetic retinopathy and other vascular complications

The volume addresses a variety of current scientific discussions about mechanisms of damage such as growth factors and the VEGF/PEDF balance in the diabetic eye, the ocular renin-angiotensin system, and leukocyte interactions with the microvasculature among others.

22 Dec 2009

Diabetes patients at higher risk from glaucoma

An estimated 3 million Americans have glaucoma, which can stealthily cause vision loss even before people realize they have the disease. People with diabetes face special risks from glaucoma. This January during Glaucoma Awareness Month, through its EyeSmart™ campaign, the American Academy of Ophthalmology in partnership with the American Glaucoma Society and the Glaucoma Research Foundation, remind Americans that knowing your glaucoma risks can save your sight and that people with diabetes need to be extra-vigilant.

19 Dec 2009

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

16 Dec 2009

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

iCo Therapeutics Inc. is pleased to announce that an overview of iCo-007, entitled "iCo-007 a VEGF "+" Agent for the Potential Treatment of Diabetic Macular Edema and Diabetic Retinopathy" will be presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics ("ISOPT"), a major international ocular conference.

3 Dec 2009

Pycnogenol can improve microcirculation, retinal edema and visual acuity, reveals study

According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy.

2 Dec 2009

New study indicates pine bark may reduce progressing advanced stages of diabetic retinopathy

According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopathy, damage to the retina caused by leaky blood vessels, is a major cause of blindness in people with diabetes and is one of the most feared diabetic complications. In

2 Dec 2009

Wnt signaling pathway plays a role in diabetic retinopathy

A group led by Dr. Jian-xing Ma at The University of Oklahoma Health Sciences Center, Oklahoma City, OK has demonstrated that the Wnt signaling pathway plays a role in diabetic retinopathy.

26 Nov 2009

Diabetic retinopathy on the rise; dilated eye exam can help prevent vision loss

The incidence of diabetes continues to increase, particularly among adolescents and young adults. The CDC projects the number of diabetic retinopathy cases will double by 2050. On World Diabetes Day, November 14, the American Academy of Ophthalmology (Academy), through its EyeSmart™ campaign, is reminding the public that an annual dilated eye exam can help prevent vision loss in people with diabetes.

13 Nov 2009

ThromboGenics issues business update for the third-quarter of 2009

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

4 Nov 2009

Multicenter study finds AMD patients can benefit from cataract surgery

This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums.

2 Nov 2009

Annual dilated eye exam helps prevent vision loss in people with diabetes

Diabetes causes more new cases of legal blindness among working-age Americans than any other disease. If diabetics are monitored regularly by their ophthalmologist, this vision loss is almost always avoidable. Yet, tragically, more than half of all people living with diabetes do not get the recommended annual dilated eye exam.

30 Oct 2009

CWRU grants licensing agreement to Bioptigen for FDOCT technology

Case Western Reserve University and University Hospitals Case Medical Center have granted to Bioptigen, of Research Triangle Park, N.C ., an exclusive intellectual property licensing agreement for Fourier domain optical coherence tomography (FDOCT), an imaging technology developed from research at the university's Department of Biomedical Engineering.

27 Oct 2009

AAO-PAAO meeting discusses tougher challenges of treating premature babies' vision

Highlights of today's Scientific Program of the 2009 American Academy of Ophthalmology (AAO) - Pan-American Association of Ophthalmology (PAAO) Joint Meeting include: John T. Flynn, MD, Columbia University School of Medicine, discussing the ever-tougher challenges Eye M.D.s face in caring for the vision of the tiniest premature babies; and a report by Bradford W. Lee, MD, Stanford University School of Medicine, on barriers to glaucoma follow-up as perceived by patients in an urban, culturally diverse clinic.

26 Oct 2009

Diabetics who are nearsighted may be less susceptible to diabetic retinopathy

Two studies are of particular note in today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO): a report by Swiss neuro-ophthalmic researchers about vision exam clues that should make ophthalmologists suspect an atypical variant of Alzheimer's disease; and new evidence from a Singapore National Eye Center study that diabetics who are nearsighted may be less susceptible to diabetic retinopathy.

26 Oct 2009

Saving sight in premature babies: The past, present and future of ROP treatment

26 Oct 2009

Study shows diabetics who are nearsighted may be less susceptible to diabetic retinopathy

26 Oct 2009

NicOx reports financial results for the first nine months of 2009

NicOx S.A. today reported financial results for the nine months ended September 30, 2009.

22 Oct 2009

Electronic eye implant mimics human retina; restores partial vision

A 50-year-old New York woman who was diagnosed with a progressive blinding disease at age 13 was implanted with an experimental electronic eye implant that has partially restored her vision. A team led by Dr. Lucian V. Del Priore at NewYork-Presbyterian Hospital/Columbia University Medical Center performed the June 26 surgery -- the first case of its kind in New York.

22 Oct 2009

Auxano point-of-care indicator system for dry eye syndrome

Auxano Diagnostics, LLC, a subsidiary of Auxano Biomedical, LLC, has announced the application of the company’s breakthrough wound care technology to the treatment of dry eye syndrome (DES) with the Auxano point-of-care indicator system.

21 Oct 2009